Evoke Pharma, Inc.
Evoke Pharma, Inc. (EVOK) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
evok · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Evoke Pharma, Inc. (EVOK) measures how much investors pay for each dollar of the company's trailing earnings. EVOK's current PE ratio of N/A is calculated by dividing its stock price of $11.00 by its TTM earnings per share of -$2.04.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2011 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Evoke Pharma, Inc.You EVOK | $19M | N/A | — | -$2.04 |
 Adial Pharmaceuticals, Inc. ADIL | $2M | N/A | — | -$11.93 |
 Biofrontera Inc. BFRI | $12M | N/A | — | -$1.04 |
 Biomerica, Inc. BMRA | $6M | N/A | — | -$2.16 |
 Meihua International Medical Technologies Co., Ltd. MHUA | $2M | 0.87x | — | $39.62 |
 NeuroSense Therapeutics Ltd. NRSN | $19M | N/A | — | -$0.44 |
 Sunshine Biopharma, Inc. SBFM | $1M | N/A | — | -$14.37 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-2.81 | — | |
2023-12-31 FY2023 | — | $-27.97 | — | |
2022-12-31 FY2022 | — | $-31.39 | — | |
2021-12-31 FY2021 | — | $-38.20 | — | |
2020-12-31 FY2020 | — | $-74.31 | — | |
2019-12-31 FY2019 | — | $-46.02 | — | |
2018-12-31 FY2018 | — | $-65.62 | — | |
2017-12-31 FY2017 | — | $-118.21 | — | |
2016-12-31 FY2016 | — | $-165.75 | — | |
2015-12-31 FY2015 | — | $-269.13 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Evoke Pharma, Inc. (EVOK) measures how much investors pay for each dollar of the company's trailing earnings. EVOK's current PE ratio of N/A is calculated by dividing its stock price of $11.00 by its TTM earnings per share of -$2.04.
Frequently asked questions
EVOK pe ratio · 6 questionsEVOK's current PE ratio is N/A as of 2026-06-09, based on a stock price of $11.00 and TTM EPS of -$2.04. Data sourced from Financial Modeling Prep via EVOK's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Evoke Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09